Sep 23, 2026 07:00AM
Sep 23, 2026 07:00AM
Sep 8, 2026 06:01AM
Sep 8, 2026 06:00AM
Sep 8, 2026 06:00AM
Sep 8, 2026 06:00AM
Sep 6, 2026 01:00AM Pulmovant to present Phase 2 mosliciguat results at ERS Congress
Sep 6, 2026 01:00AM
Sep 6, 2026 01:00AM
Sep 6, 2026 01:00AM
Aug 27, 2026 03:29PM
Aug 27, 2026 03:29PM
Aug 27, 2026 03:29PM
Aug 27, 2026 03:28PM FDA approves Priovant's brepocitinib for dermatomyositis
Aug 27, 2026 03:28PM
Aug 27, 2026 03:28PM
Aug 6, 2026 07:00AM
Aug 6, 2026 07:00AM
Aug 6, 2026 07:00AM
Jul 23, 2026 04:05PM
May 21, 2026 09:17AM Roivant Sciences (ROIV) PT Raised at TD Cowen as 'IMVT-1402 Shines In D2T RA'
May 21, 2026 06:20AM
May 20, 2026 07:00AM
Apr 2, 2026 05:00AM
Apr 2, 2026 05:00AM
Apr 2, 2026 05:00AM
Apr 2, 2026 05:00AM
Mar 28, 2026 03:00PM New England Journal of Medicine publishes VALOR trial results for brepocitinib
Mar 28, 2026 03:00PM
Mar 3, 2026 07:00AM
Mar 3, 2026 07:00AM
Feb 10, 2026 06:52AM
Feb 6, 2026 07:00AM
Feb 6, 2026 07:00AM
Feb 6, 2026 07:00AM Priovant Announces Positive Phase 2 Results for Brepocitinib in Cutaneous Sarcoidosis (CS)
Feb 6, 2026 07:00AM
Oct 1, 2025 01:20PM
Oct 1, 2025 01:13PM
Sep 3, 2025 01:01PM
Sep 3, 2025 01:01PM
Apr 21, 2025 07:02AM
Apr 21, 2025 07:00AM Immunovant Announces Next Phase of Growth with Roivant Including Changes to its Leadership Team and Additional Indications Sjögren’s Disease (SjD) and Cutaneous Lupus Erythematosus (CLE) for IMVT-1
Nov 12, 2024 07:00AM
Oct 28, 2024 09:25AM
Oct 28, 2024 09:25AM
Sep 18, 2024 07:30AM
Sep 18, 2024 07:30AM
Sep 11, 2024 06:36AM
Sep 9, 2024 07:02AM Roivant Sciences (ROIV) Provides Update on Graves’ Disease Development Program
Sep 9, 2024 07:00AM

334,279 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All